ATE425251T1 - Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen - Google Patents

Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen

Info

Publication number
ATE425251T1
ATE425251T1 AT99914725T AT99914725T ATE425251T1 AT E425251 T1 ATE425251 T1 AT E425251T1 AT 99914725 T AT99914725 T AT 99914725T AT 99914725 T AT99914725 T AT 99914725T AT E425251 T1 ATE425251 T1 AT E425251T1
Authority
AT
Austria
Prior art keywords
mimic
carbohydrates
vaccines containing
streptococcus group
antidiotypic
Prior art date
Application number
AT99914725T
Other languages
English (en)
Inventor
Giuseppe Teti
Luciano Polonelli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE425251T1 publication Critical patent/ATE425251T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4233—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-bacterial Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99914725T 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen ATE425251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds

Publications (1)

Publication Number Publication Date
ATE425251T1 true ATE425251T1 (de) 2009-03-15

Family

ID=10830608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914725T ATE425251T1 (de) 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen

Country Status (9)

Country Link
US (2) US6676938B1 (de)
EP (1) EP1071763B1 (de)
JP (2) JP4446601B2 (de)
AT (1) ATE425251T1 (de)
CA (1) CA2325566C (de)
CY (1) CY1109140T1 (de)
DE (1) DE69940545D1 (de)
GB (1) GB9808327D0 (de)
WO (1) WO1999054457A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181058A2 (de) * 1999-05-27 2002-02-27 Max-Delbrück-Centrum Für Molekulare Medizin Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
JP2008525033A (ja) * 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｂ群連鎖球菌
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP2537857B1 (de) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutante Formen von Streptolysin O
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (de) 2010-10-01 2018-06-27 ModernaTX, Inc. Manipulierte nukleinsäuren und anwendungsverfahren dafür
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
EP3773348B1 (de) 2018-04-10 2025-04-02 Alps Holding Llc Wirbelzwischenkörperkäfig mit ober- und unterseiten mit maschenstrukturen, säulen und schlitzen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
JP2000512490A (ja) * 1996-05-29 2000-09-26 デレク ナイジェル ジョン ハート 樹状細胞のレセプター
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
CA2317029A1 (en) * 1997-12-31 1999-07-08 Seth H. Pincus A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof in a vaccine

Also Published As

Publication number Publication date
US6900302B2 (en) 2005-05-31
EP1071763B1 (de) 2009-03-11
JP2009179645A (ja) 2009-08-13
CA2325566C (en) 2011-02-08
JP4446601B2 (ja) 2010-04-07
US20040101536A1 (en) 2004-05-27
CY1109140T1 (el) 2014-07-02
JP2002512026A (ja) 2002-04-23
CA2325566A1 (en) 1999-10-28
DE69940545D1 (de) 2009-04-23
GB9808327D0 (en) 1998-06-17
EP1071763A1 (de) 2001-01-31
US6676938B1 (en) 2004-01-13
WO1999054457A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
ATE425251T1 (de) Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
FI882173A7 (fi) Synteettinen peptidiantigeeni HIV-2-tartunnan toteamiseksi.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
EP0344940A3 (de) Antikörper gegen latente Proteine von menschlichen Papillomavirus, diagnostische Systeme und Methoden
IT8819187A0 (it) Sistema di bilanciamento mediante pistone a vapore in trazione, particolarmente per turbomotori agas.
TR199801722T2 (xx) Peptit imm�nojenler.
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
ATE317441T1 (de) Cathepsin-02-protease
NO910656L (no) Sperrevaeske-tetningsanordning for turbokompressor.
ATE197506T1 (de) Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
WO1998039450A3 (de) Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen
DE3382718D1 (de) Peptide, die eine Immunogen-Lage des Poliovirus des Sabin-Stammes enthalten.
NO910655D0 (no) Sperrevaeske-tetningsanordning for turbokompressor.
FI911973A0 (fi) Traodaktigt hemagglutinin av b. pertussis-bacill.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
FI854839A0 (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
ATE174963T1 (de) Klonierung und expression eines rhoptry- assoziierten proteins aus p. falciparum
USD149243S (en) Design fob a velocipede

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071763

Country of ref document: EP